Zhuhai Sailong Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020
October 27, 2020 at 12:56 pm
Share
Zhuhai Sailong Pharmaceutical Co.,Ltd. announced earnings results for the nine months ended September 30, 2020. For the nine months, the company announced sales was CNY 126.844 million compared to CNY 214.993 million a year ago. Operating loss was CNY 19.968 million compared to operating Income of CNY 21.588 million a year ago. Net loss was CNY 21.568 million compared to net income of CNY 18.896 million a year ago. Basic loss per share from continuing operations was CNY 0.1225 compared to basic earnings per share from continuing operations of CNY 0.1074 a year ago.
Sailong Pharmaceutical Group Co Ltd, formerly Zhuhai Sailong Pharmaceutical Co Ltd, is a China-based company principally engaged in the research and development, production and sales of pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and preparations, as well as providing technical services. The Companyâs main products include monosialin tetrahexose ganglioside sodium injections, brain protein hydrolyzate for injections, clindamycin phosphate for injections, pantoprazole sodium for injections and milrinon injections, among others. Through its subsidiaries, the Company is also engaged in the sales of scraps, provision of technical services and sales promotion. The Company mainly conducts its businesses with domestic market.
SAILONG PHARMACEUTICAL GROUP CO.,LTD. 
